◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY
Home › All stocks › 0-9 › 6132

HJ Science Co., Ltd. (6132) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-10-02

HJ Science Co., Ltd. (6132) operates in the Biotechnology industry and is headquartered in Chengdu, China with about 113 employees. In the fiscal year ended 2025-12-31, 6132 reported CNY 13M in revenue and (CNY 135M) in net income.

HJ Science Co., Ltd. engages in research and development of new small molecule drugs. The company focuses on metabolic diseases, oncology, and autoimmune disorders.

Interactive charts & full statements →

6132 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-31
Total RevenueCNY 13MCNY 2M
Operating Income (EBIT)(CNY 125M)(CNY 85M)
Net Income(CNY 135M)(CNY 202M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

6132 Free Cash Flow History

6132 Balance Sheet History

Balance sheet2025-12-312024-12-31
Total AssetsCNY 433MCNY 430M
Total LiabilitiesCNY 96MCNY 54M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 6132 viewer.

Other Companies in Biotechnology

← 612AAll “0-9” companies6133 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.